Nikki D’Arcy

Apax Partners LLP engages in providing investment services. It focuses on investing in firms across the global sectors such as technology and telecommunications, services, healthcare, and consumer. The company was founded by Ronald Mourad Cohen and Alan J. Patricof in 1969 and is headquartered in London, the United Kingdom.

Cancer Therapeutics CRC Pty Ltd. engages in research and development novel oncology drug and clinical diseases. It focuses in recombinant protein production, structural biology, DMPK, and translational cancer biology. The company was founded in 2007 and is headquartered in Melbourne, Australia.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses

Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London.

Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia.

Paras Ltd. provides information management and strategy consultancy services to the energy sector. The company was founded by Hamish Angus Munro Wilson in 1993 and is headquartered in Abingdon, the United Kingdom.

ADC Products (UK) Ltd. operates as a clinical stage biotechnology company. It develops pyrrolobenzodiazepines for antibody-drug conjugation. The company was founded in November 2000 and is headquartered in Reading, the United Kingdom.

Xenva Ltd. provides boutique management services. The company was founded on June 19, 1997 and is headquartered in Hampshire, the United Kingdom.

AusBiotech Ltd. operates as an Australian biotechnology membership company. The private company is based in Melbourne, Australia. and has subsidiaries in Australia. The company was founded by Liz Dallimore. Lorraine Chiroiu has been the CEO of the company since 2008.

MedImmune Pharma BV develops, manufactures and markets formulations for use in immunization programs. It specializes in the production of a vaccine called Amifostine. The company was founded in 1993 and is headquartered in Nijmegen, Belgium.

Elastagen Pty Ltd. produces and develops synthetic human elastin for medical device applications. Its products include skin rejuvenation, scar remodeling, skin tissue repair, wound healing, surgical glues and sealants. The firm developed a Elastatherapy treatments which offer the chance to restore the levels of Elastin in human skin, with benefits anticipated in both medical dermatology and cosmetic applications. The company was founded by Anthony Weiss in 2003 and is headquartered in Sydney, Australia.

Tokamak Energy Ltd. provides medical and biotechnology services. It develops the potential to use fusion neutrons for a variety of applications from material treatments to medical applications or low cost hydrogen production. The company was founded by David Richard Kingham, Mikhail Gryaznevich and Alan Sykes in 2009 and is headquartered in Abingdon, the United Kingdom.

Vaxxas Pty Ltd. develops and commercializes needle-free vaccine delivery system solutions. Its flagship products, Nanopatch, consists of an array of thousands of vaccine coated microprojections that perforate into the outer layers of the skin when applied with an applicator device. The tips of Nanopatch's microprojections are coated with a vaccine material and release this material directly to the large numbers of key immune cells immediately below the skin surface. The company was founded by Mark Kendall in August 2011 and is headquartered in Sydney, Australia.

Topivert Pharma Ltd. is a British pharmaceutical company founded in 2011. The private company develops non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal.

MiReven Pty Ltd. operates as an Australian biopharmaceutical company. The private company is based in Nedlands, Australia.

Kesios Therapeutics Ltd. provides biotechnology services. It develops novel therapeutics for the treatment of multiple myeloma and other cancers where there are significant unmet medical needs. The company was founded by Menotti Ruvo, Laura Tornatore, and Guido Franzoso on July 13, 2012 and is headquartered in Cambridge, the United Kingdom.

ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.

MecRx Pty Ltd. develops drugs for treatment of cancer. The company was founded by Ian Holmes, Jo Alcindor, Tom Peat and Janet Newman in 2013 and is headquartered in Melbourne, Australia.

Mironid Ltd. develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. The company was founded by Miles Houslay, Paul Barton Rodgers, Elizabeth Fairley, Julia Adam, David Adams and Nigel Pyne in 2014 and is headquartered in North Lanarkshire, the United Kingdom.

Spirogen SARL is a Swiss company. 'The private company is based in Lausanne, Switzerland. The company was founded by Christopher John Martin.

OncoRes Medical Pty Ltd. develops an imaging medical device which provides micro-scale images of tissue stiffness and elasticity information to surgeons. The company is headquartered in Nedlands, Australia.

Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom.

Longas Technologies Pty Ltd. is engaged in developing next generation sequencing (NGS) technologies. The company was founded by Ian Charles, Aaron Darling, and Catherine Burke in 2015 and is headquartered in Sydney, Australia.

Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA.

Osivax SAS engages in the development of infectious diseases vaccines and immunotherapies based on oligoDOM? proprietary technology. It operates in the influenza vaccine "INFLUENZA - OVX836" business segment. The company was founded by Alexandre Le Vert, Florence Nicolas and Fergal Hill on May 15, 2017 and is headquartered in Lyon, France.

Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware.

Respirion Pharmaceuticals Pty Ltd. operates as a biotechnology firm. It focuses on development new treatments for respiratory diseases. The company was founded by Barry Clements in 2018 and is headquartered in Iluka, Australia.